SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Divi's Laboratories inks supply agreement with global pharmaceuticals firm

21 Apr 2025 Evaluate

Divi's Laboratories has inked a supply agreement with a global pharmaceuticals firm. Under the long-term agreement, the company will be manufacturing and supplying advanced intermediates as per the commercial terms agreed between the parties. The company expects meaningful revenue contribution from this long-term agreement.

The company is planning for capacity addition at its manufacturing facilities with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals.

Divi's Laboratories is one of the leading pharmaceutical companies in the world.

Divis Lab Share Price

6228.95 -68.55 (-1.09%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×